ArticleObesity surgery2025
Analyzing the Adequacy of BMI-Tiered Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in the Bariatric Surgery Population Based on Anti-Factor Xa Assay Data.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveVenous thromboembolism (VTE) events remain a top cause of morbidity and mortality following bariatric surgery. Thus, prophylactic BMI-tiered low-molecular-weight heparin (LMWH) regimens have been implemented. The adequacy of such prophylaxis has been questioned. The aim of this study was to evaluate the adequacy of BMI-based VTE prophylaxis using the anti-factor Xa (AFXa) assay in patients with obesity undergoing bariatric surgery.
methodsThis was a retrospective review of adult patients undergoing Roux-en-Y gastric bypass (RNYGB), laparoscopic sleeve gastrectomy (LSG), or revisional bariatric procedures, at a high-volume, community-based institution, between January 2017 and December 2020. Patients received twice daily, BMI-tiered dosing of LMWH post-operatively. Individuals with BMI < 50 kg/m
resultsA total of 203 patients (67% female) were included. Median age and BMI were 46 years and 50.79 kg/m
conclusionBMI-tiered LMWH dosing for VTE prophylaxis in this bariatric surgery population was inadequate in achieving prophylaxis in greater than 37% of patients. This rate is substantially different than previous reports.
Indexed as
Identifiers
40615759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.